United Capital Financial Advisors’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-12,891
Closed -$269K 1085
2024
Q4
$269K Buy
12,891
+448
+4% +$9.84K ﹤0.01% 919
2024
Q3
$303K Sell
12,443
-444
-3% -$11.9K ﹤0.01% 868
2024
Q2
$324K Buy
12,887
+886
+7% +$25.1K ﹤0.01% 822
2024
Q1
$359K Buy
12,001
+10
+0.1% +$294 ﹤0.01% 826
2023
Q4
$382K Sell
11,991
-15,851
-57% -$498K ﹤0.01% 799
2023
Q3
$982K Sell
27,842
-814
-3% -$31K 0.01% 519
2023
Q2
$1.09M Sell
28,656
-848
-3% -$33.8K 0.01% 536
2023
Q1
$1.11M Sell
29,504
-1,636
-5% -$62.9K 0.01% 552
2022
Q4
$1.32M Sell
31,140
-4,693
-13% -$193K 0.01% 556
2022
Q3
$1.15M Sell
35,833
-1,068
-3% -$37.5K 0.01% 583
2022
Q2
$1.2M Buy
36,901
+2,503
+7% +$81.1K 0.01% 601
2022
Q1
$1.25M Sell
34,398
-1,934
-5% -$66.4K 0.01% 624
2021
Q4
$1.44M Buy
36,332
+33
+0.1% +$1.38K 0.01% 608
2021
Q3
$1.59M Sell
36,299
-189,998
-84% -$8.53M 0.01% 570
2021
Q2
$9.24M Buy
226,297
+15,161
+7% +$585K 0.05% 284
2021
Q1
$6.93M Buy
211,136
+49,039
+30% +$1.84M 0.04% 308
2020
Q4
$6.59M Buy
+162,097
New +$6.06M 0.04% 307

Other funds holding GMAB

United Capital Financial Advisors's GMAB Position: Q1 2025 in Review

United Capital Financial Advisors sold out of Genmab (GMAB) in Q1 2025, closing a stake of 12,891 shares — an estimated $269K sold.

United Capital Financial Advisors first reported a position in GMAB in Q4 2020 and held it in 17 quarters. The position peaked at $9.24M in Q2 2021. 219 funds tracked by Wall St. Rank hold GMAB as of Q1 2025.

  • United Capital Financial Advisors reported no remaining Genmab position as of Q1 2025 after selling out during the quarter.
  • United Capital Financial Advisors sold 12,891 Genmab shares in Q1 2025, an estimated $269K.
  • United Capital Financial Advisors first reported a position in Genmab in Q4 2020 and held it in 17 quarters.
  • United Capital Financial Advisors's Genmab position peaked at $9.24M in Q2 2021.
  • 219 funds tracked by Wall St. Rank held Genmab as of Q1 2025.

Based on United Capital Financial Advisors's 13F filing for Q1 2025, filed 13 May 2025.